Nifurtimox + eflornithine promising for trypanosomiasis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1616, 2007-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Say goodnight to African sleeping sickness with eflornithine

By  

Inpharma, Vol. 1, Iss. 1630-1631, 2008-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Development of eflornithine [difluoromethylornithine, DFMO] has been discontinued

By  

Inpharma, Vol. 1, Iss. 1424, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Effective measures for controlling trypanosomiasis

By Nok Andrew J  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 15, 2005-12 ,pp. : 2645-2653

Informa Healthcare

Access to resources Recommend Favorite

Developments in the treatment of leishmaniasis and trypanosomiasis

By Olliaro Piero   Lazdins Janis   Guhl Felipe  

Expert Opinion on Emerging Drugs, Vol. 7, Iss. 1, 2002-05 ,pp. : 61-67

Informa Healthcare

Access to resources Recommend Favorite

The pharmacokinetics of eflornithine (α-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness

By Na-Bangchang K.   Doua F.   Konsil J.   Hanpitakpong W.   Kamanikom B.   Kuzoe F.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 4, 2004-06 ,pp. : 269-278

Springer Publishing Company

Access to resources Recommend Favorite